Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

J&J Disputes Terms Of Arthritis Pact

by Lisa M. Jarvis
June 1, 2009 | A version of this story appeared in Volume 87, Issue 22

Johnson & Johnson is throwing a wrench in Merck & Co.'s planned acquisition of Schering-Plough by vying for control of the arthritis drug Remicade, which it comarkets with Schering-Plough. Under the marketing pact, J&J has the right to take full control of both Remicade and golimumab, a next-generation arthritis therapy, if Schering-Plough is sold. To work around this stipulation, Merck and Schering-Plough structured their deal as a reverse merger in which Schering-Plough will be the surviving company but be renamed Merck. J&J isn't buying that argument, and it has initiated arbitration to settle the dispute. The process will take nine to 12 months, meaning the matter won't be resolved until after the merger is completed. Leerink Swann stock analyst Seamus Fernandez believes Merck will likely win the case because of a poorly written contract between J&J and Schering-Plough. Remicade brought in about $2 billion in sales last year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.